Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31651386 | 1.00 | PDE5A (0.82) | PDE5A | |
| SCHEMBL30575409 | 0.96 | PDE5A (0.82) | PDE5A | |
| SCHEMBL20569037 | 0.96 | PDE5A (0.82) | PDE5A | |
| SCHEMBL20568055 | 0.93 | PDE5A (0.88) | PDE5A | |
| SCHEMBL30575418 | 0.91 | PDE5A (0.76) | PDE5A | |
| SCHEMBL20568047 | 0.91 | PDE5A (0.76) | PDE5A | |
| SCHEMBL30823657 | 0.90 | PDE5A (1.00) | PDE5A | |
| SCHEMBL22028290 | 0.90 | PDE5A (1.00) | PDE5A | |
| SCHEMBL20568231 | 0.90 | PDE5A (0.75) | PDE5A | |
| SCHEMBL30575412 | 0.90 | PDE5A (0.75) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696376-A2 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2026-02-18 | — | — | EP | claimed |
| EP-3630769-B1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2025-07-02 | — | — | EP | claimed |
| US-20250195522-A1 | TRANSDERMAL DOSAGE FORM, FOR PROMOTING LOCAL BLOOD FLOW, OF DUAL-ACTING PDE5 INHIBITOR/ORGANIC NITRATE ESTER | UIF (UNIVERSITY INDUSTRY FOUNDATION), YONSEI UNIVERSITY (KR) | 2025-06-19 | — | — | US | claimed |
| US-20250161309-A1 | TOPICAL COMPOSITIONS AND USES THEROF | TOPADUR PHARMA AG (CH) | 2025-05-22 | — | — | US | claimed |
| EP-4487852-A1 | TRANSDERMAL DOSAGE FORM, FOR PROMOTING LOCAL BLOOD FLOW, OF DUAL-ACTING PDE5 INHIBITOR/ORGANIC NITRATE ESTER | Yonsei University, University-Industry Foundation(UIF). (KR) | 2025-01-08 | — | — | EP | claimed |
| EP-4486349-A1 | TOPICAL COMPOSITIONS AND USES THEROF | Topadur Pharma AG (CH) | 2025-01-08 | — | — | EP | claimed |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2024-10-31 | — | — | US | claimed |
| CN-118063458-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-05-24 | — | — | CN | claimed |
| WO-2023166013-A9 | TOPICAL COMPOSITIONS AND USES THEROF | TOPADUR PHARMA AG (CH) | 2024-05-23 | — | — | WO | claimed |
| CN-110621676-B | Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-02-09 | — | — | CN | claimed |
| WO-2023166013-A1 | TOPICAL COMPOSITIONS AND USES THEROF | TOPADUR PHARMA AG (CH) | 2023-09-07 | — | — | WO | claimed |
| WO-2023167503-A1 | TRANSDERMAL DOSAGE FORM, FOR PROMOTING LOCAL BLOOD FLOW, OF DUAL-ACTING PDE5 INHIBITOR/ORGANIC NITRATE ESTER | 연세대학교 산학협력단 | 2023-09-07 | — | — | WO | claimed |
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-03-10 | — | — | US | claimed |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2021-10-26 | — | — | US | claimed |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2020-06-11 | — | — | US | claimed |
| EP-3630769-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2020-04-08 | — | — | EP | claimed |
| CN-110621676-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2019-12-27 | — | — | CN | claimed |
| WO-2018215433-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2018-11-29 | — | — | WO | claimed |
| EP-4696376-A2 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | Topadur Pharma AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2018215433-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073529-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | PDE5A 1/4885 |
| US-20250161309-A1 | TOPICAL COMPOSITIONS AND USES THEROF | PDE5A, PDE3A, PDE3B | PDE5A 1/4885 |
| US-20250195522-A1 | TRANSDERMAL DOSAGE FORM, FOR PROMOTING LOCAL BLOOD FLOW, OF DUAL-ACTING PDE5 INHIBITOR/ORGANIC NITRATE ESTER | PDE5A, PDE3B, PDE3A | PDE5A 1/4885 |
| US-11155558-B2 | Dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | PDE7A, GNAO1, PDE3A | PDE5A 11/4885 |
| US-20200181149-A1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, PDE3A, PDE9A | PDE5A 10/4885 |
| US-20240360136-A1 | DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE1A, PDE2A | PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.